JP5893616B2 - 注射用徐放性製剤 - Google Patents

注射用徐放性製剤 Download PDF

Info

Publication number
JP5893616B2
JP5893616B2 JP2013517506A JP2013517506A JP5893616B2 JP 5893616 B2 JP5893616 B2 JP 5893616B2 JP 2013517506 A JP2013517506 A JP 2013517506A JP 2013517506 A JP2013517506 A JP 2013517506A JP 5893616 B2 JP5893616 B2 JP 5893616B2
Authority
JP
Japan
Prior art keywords
solution
preparation
active ingredient
crystals
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013517506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543481A (ja
JP2013543481A5 (https=
Inventor
隆 中川
隆 中川
宣雅 小関
宣雅 小関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JP2013543481A publication Critical patent/JP2013543481A/ja
Publication of JP2013543481A5 publication Critical patent/JP2013543481A5/ja
Application granted granted Critical
Publication of JP5893616B2 publication Critical patent/JP5893616B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013517506A 2010-10-18 2011-10-18 注射用徐放性製剤 Expired - Fee Related JP5893616B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39406910P 2010-10-18 2010-10-18
US61/394,069 2010-10-18
PCT/JP2011/074375 WO2012053654A1 (en) 2010-10-18 2011-10-18 Sustained-release formulation for injection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016033019A Division JP6173502B2 (ja) 2010-10-18 2016-02-24 注射用徐放性製剤

Publications (3)

Publication Number Publication Date
JP2013543481A JP2013543481A (ja) 2013-12-05
JP2013543481A5 JP2013543481A5 (https=) 2014-12-04
JP5893616B2 true JP5893616B2 (ja) 2016-03-23

Family

ID=45933169

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013517506A Expired - Fee Related JP5893616B2 (ja) 2010-10-18 2011-10-18 注射用徐放性製剤
JP2016033019A Expired - Fee Related JP6173502B2 (ja) 2010-10-18 2016-02-24 注射用徐放性製剤
JP2017131059A Expired - Fee Related JP6410889B2 (ja) 2010-10-18 2017-07-04 注射用徐放性製剤
JP2018179030A Pending JP2019006822A (ja) 2010-10-18 2018-09-25 注射用徐放性製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016033019A Expired - Fee Related JP6173502B2 (ja) 2010-10-18 2016-02-24 注射用徐放性製剤
JP2017131059A Expired - Fee Related JP6410889B2 (ja) 2010-10-18 2017-07-04 注射用徐放性製剤
JP2018179030A Pending JP2019006822A (ja) 2010-10-18 2018-09-25 注射用徐放性製剤

Country Status (7)

Country Link
US (3) US9469630B2 (https=)
EP (1) EP2629775A4 (https=)
JP (4) JP5893616B2 (https=)
KR (1) KR101936968B1 (https=)
CN (3) CN107595771A (https=)
CA (1) CA2814840C (https=)
WO (1) WO2012053654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
WO2014084921A1 (en) * 2012-11-27 2014-06-05 Rose Stuart Pharmaceutical manufacturing method and compositions
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
KR101792414B1 (ko) * 2016-05-19 2017-11-01 삼성전기주식회사 박막 커패시터 및 그 제조방법
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CA3034995A1 (en) * 2016-08-31 2018-03-08 Sumitomo Dainippon Pharma Co., Ltd. Aqueous suspension preparation
US10252229B2 (en) * 2017-06-30 2019-04-09 Snowie LLC System comprising a pump attached to a tank casing for mixing a fluid
SG11202008233WA (en) 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation with controlled dissolution
SG11202008204QA (en) * 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation
JP7214103B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JPWO2020179925A1 (https=) * 2019-03-07 2020-09-10
CN110478131B (zh) * 2019-08-05 2022-01-11 思必康（厦门）新材料有限公司 一种pH响应变色的纱布及其制备方法和该纱布的应用
US11041740B1 (en) 2019-12-20 2021-06-22 EmpNia Inc. Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings
CN119431400A (zh) * 2020-03-27 2025-02-14 波士顿科学国际有限公司 用于使药物结晶的方法
EP4196106A1 (en) * 2020-08-11 2023-06-21 Auxilla Pharmaceuticals and Research LLP A non-aqueous suspension of anticancer agent
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
JP2024511693A (ja) 2021-03-31 2024-03-15 四川科▲倫▼▲薬▼物研究院有限公司 注射可能なルラシドン懸濁液及びその製造方法
CN120078778A (zh) * 2024-09-25 2025-06-03 山东百诺医药股份有限公司 一种伏硫西汀酯药物组合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
KR100537713B1 (ko) 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-메틸-티에노-벤조디아제핀 제제
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
FI105074B (fi) 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
PL196821B1 (pl) 1998-09-30 2008-02-29 Lilly Co Eli Sól olanzapiny i jej zastosowanie
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
DE10218110A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP4610485B2 (ja) 2003-07-29 2011-01-12 大日本住友製薬株式会社 イミド化合物の製造方法
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
CN101166514A (zh) 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
CN102048734B (zh) * 2005-05-26 2013-11-20 大日本住友制药株式会社 药物组合物
JP4866349B2 (ja) * 2005-06-13 2012-02-01 大日本住友製薬株式会社 可溶化型製剤
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007106768A2 (en) 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
WO2009074666A1 (en) 2007-12-13 2009-06-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN107595771A (zh) 2018-01-19
CA2814840C (en) 2018-08-28
CN103249416B (zh) 2019-06-04
JP6173502B2 (ja) 2017-08-02
US20190010149A1 (en) 2019-01-10
KR20130139978A (ko) 2013-12-23
CN103249416A (zh) 2013-08-14
EP2629775A4 (en) 2014-06-11
KR101936968B1 (ko) 2019-01-09
JP2013543481A (ja) 2013-12-05
US20160158228A1 (en) 2016-06-09
JP2019006822A (ja) 2019-01-17
US9469630B2 (en) 2016-10-18
CA2814840A1 (en) 2012-04-26
JP2016128503A (ja) 2016-07-14
JP6410889B2 (ja) 2018-10-24
JP2017206543A (ja) 2017-11-24
EP2629775A1 (en) 2013-08-28
WO2012053654A1 (en) 2012-04-26
CN107625728A (zh) 2018-01-26
US20120091022A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
JP6410889B2 (ja) 注射用徐放性製剤
JP6306609B2 (ja) 医薬組成物
JP6012637B2 (ja) アリピプラゾール凍結乾燥製剤
JP7312523B2 (ja) フルベストラント配合物およびその使用方法
CN102970978A (zh) 活性药物成分的颗粒加工方法
JP2013543481A5 (https=)
CN101322682A (zh) 难溶性药物纳米粒的制备方法
JP2007532619A (ja) 懸濁したガラス粒子を含有する液体
JP2022188127A (ja) 注射可能な懸濁液
CN103263385B (zh) 一种塞来昔布长效纳米注射剂及其制备方法
CN106474058B (zh) 具有延长的保质期的阿立哌唑可注射悬浮液制剂
NO880403L (no) Parenterale suspensjoner.
JP2025024083A (ja) 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液
CN105030663B (zh) 一种溶液型醋酸曲安奈德注射液的制备方法
CN118574605A (zh) 奥氮平、其组合物及其使用方法
WO2011016436A1 (ja) ポリ乳酸微粒子含有凍結乾燥組成物の製造方法
CN101780084A (zh) 一种以左旋亚叶酸或其盐为主要成分的注射用组合物
WO2003099288A1 (en) Medicinal composition
TWI584823B (zh) 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
WO2011016435A1 (ja) ポリ乳酸粒子含有凍結乾燥組成物の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160224

R150 Certificate of patent or registration of utility model

Ref document number: 5893616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees